MorphoSys AG (ETR:MOR) received a €84.00 ($98.82) target price from stock analysts at Independent Research GmbH in a report released on Wednesday. The brokerage currently has a “buy” rating on the stock.

A number of other equities analysts also recently issued reports on the company. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on MorphoSys AG and gave the stock a “neutral” rating in a research report on Thursday, September 7th. Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, August 31st. J P Morgan Chase & Co reissued a “neutral” rating on shares of MorphoSys AG in a research note on Monday, July 17th. HSBC Holdings plc set a €59.00 ($69.41) price target on shares of MorphoSys AG and gave the company a “neutral” rating in a research note on Friday, July 14th. Finally, Berenberg Bank set a €68.00 ($80.00) target price on MorphoSys AG and gave the company a “buy” rating in a report on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of €74.00 ($87.06).

MorphoSys AG (ETR MOR) traded up 1.835% during midday trading on Wednesday, reaching €74.131. The company’s stock had a trading volume of 3,578 shares. The stock’s market cap is €2.15 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €74.34. The stock’s 50 day moving average price is €63.99 and its 200-day moving average price is €60.66.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with's FREE daily email newsletter.